Tuomo Alanko

Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer

Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Petri Bono et al. · New England Journal of Medicine · 2006 · 1.4K citations

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Pembrolizumab Versus Paclitaxel, Gastrointestinal Oncology, Medicine +7

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil et al. · Journal of Clinical Oncology · 2019 · 679 citations · Full text

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

Heikki Joensuu, Petri Bono, Vesa Kataja et al. · Journal of Clinical Oncology · 2009 · 458 citations · Full text

Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

Tuuli Ranki, Sari Pesonen, Akseli Hemminki et al. · Journal for ImmunoTherapy of Cancer · 2016 · 198 citations · Full text